Spanish Red Biotech Pipeline

Gilead Sciences

Sacituzumab govitecan-hziy + pembrolizumab

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: Adjuvant triple-negative breast cancer
Phase: 3Phase III in Spain, 2Phase II in Spain, 1Phase I in Spain